Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer

Author:

Holland Levi,Bhanvadia Raj,Ibeziako Nathanaelle,Taylor Jacob,Gerlt DeitrichORCID,Chaplin Iftach,Bagrodia Aditya,Desai Neil,Gaston Kris,Lotan Yair,Margulis Vitaly,Zhang Tian,Cole Suzanne,Woldu SolomonORCID

Publisher

Elsevier BV

Reference31 articles.

1. SEER*Explorer. SEER Cancer Statistics. National Cancer Institute. Published April 19, 2023. Accessed October 30, 2023. https://seer.cancer.gov/statistics-network/explorer/.

2. Real-world survival outcomes associated with first-line immunotherapy, targeted therapy, and combination therapy for metastatic clear cell renal cell carcinoma;Chakiryan;JAMA Netw Open,2021

3. Cancer statistics, 2023;Siegel;CA Cancer J Clin,2023

4. Immunotherapies in genitourinary oncology: Where are we now? Where are we going?;Jang;Cancers,2021

5. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial;Balar;Lancet Lond Engl,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3